Effect of Feedback-Based Balance Training on Balance and Gait in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy
Effects of Feedback-Based Balance Training on Balance and Gait Performance in Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Randomized Controlled Trial
1 other identifier
interventional
70
1 country
1
Brief Summary
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of cancer treatment that can cause numbness, tingling, pain, balance problems, and difficulty walking. These symptoms may increase the risk of falls and reduce independence and quality of life in cancer survivors. The purpose of this study is to determine whether adding feedback-based balance training to conventional physiotherapy improves balance and walking ability in cancer patients with CIPN. Participants will be randomly assigned to one of two groups. One group will receive conventional physiotherapy along with feedback-based balance and gait training, while the other group will receive conventional physiotherapy alone. The intervention will be provided twice per week for four weeks. Balance, gait performance, neuropathy symptoms, and fear of falling will be assessed before and after the intervention using standardized clinical outcome measures. The findings of this study may help identify effective rehabilitation strategies to improve balance and mobility in cancer patients affected by chemotherapy-induced peripheral neuropathy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 29, 2025
CompletedFirst Submitted
Initial submission to the registry
January 18, 2026
CompletedFirst Posted
Study publicly available on registry
January 26, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 29, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 29, 2026
CompletedJanuary 26, 2026
January 1, 2026
3 months
January 18, 2026
January 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Balance Performance
Balance performance will be evaluated using the Berg Balance Scale (BBS), a 14-item standardized clinical assessment with total scores ranging from 0 to 56, where higher scores indicate better balance.
Baseline and immediately after completion of the 4-week intervention
Secondary Outcomes (2)
Gait Performance
Baseline and immediately after completion of the 4-week intervention
Chemotherapy-Induced Peripheral Neuropathy Symptoms
Baseline and immediately after completion of the 4-week intervention
Study Arms (2)
Feedback-Based Balance Training Plus Conventional Physiotherapy
EXPERIMENTALParticipants in this arm will receive conventional physiotherapy combined with feedback-based balance and gait training. Conventional physiotherapy will include strengthening, flexibility, and general balance exercises. Feedback-based balance training will consist of task-oriented balance and gait activities incorporating visual and verbal feedback, mirror-based exercises, and functional gait tasks designed to challenge postural control and coordination. Sessions will be supervised, last approximately 30 minutes, and will be conducted twice per week for four weeks.
Conventional Physiotherapy
ACTIVE COMPARATORParticipants in this arm will receive conventional physiotherapy focused on strengthening, flexibility, and general balance exercises commonly used in the rehabilitation of patients with peripheral neuropathy. Sessions will be supervised, last approximately 30 minutes, and will be conducted twice per week for four weeks.
Interventions
Feedback-based balance and gait training will include structured, task-oriented balance and walking activities designed to challenge postural control and coordination. The intervention will incorporate visual and verbal feedback provided by the therapist, mirror-based exercises, and functional gait tasks such as obstacle negotiation and controlled walking activities. Training will be supervised and delivered in sessions lasting approximately 30 minutes, twice per week for four weeks. This intervention will be provided in addition to conventional physiotherapy.
Conventional physiotherapy will include standard rehabilitation exercises commonly used for patients with peripheral neuropathy, such as strengthening exercises, flexibility exercises, and general balance training. Sessions will be supervised by a physiotherapist and delivered for approximately 30 minutes per session, twice per week for four weeks.
Eligibility Criteria
You may qualify if:
- Adults aged 30 to 60 years
- Diagnosed with breast, rectal, or stomach cancer
- History of treatment with neurotoxic chemotherapy
- Presence of chemotherapy-induced peripheral neuropathy as indicated by an EORTC CIPN20 total score of 24 or higher
- Ability to walk independently for at least 6 meters, with or without an assistive device
- Medically stable and able to participate in physiotherapy
You may not qualify if:
- Peripheral neuropathy due to causes other than chemotherapy (e.g., diabetes mellitus)
- History of neurological disorders affecting balance or gait (e.g., stroke, Parkinson's disease)
- Severe musculoskeletal conditions affecting balance or lower limb function
- Active foot ulcers, infections, or soft tissue injuries
- Severe visual impairment affecting balance
- Any medical condition that, in the investigator's judgment, would interfere with safe participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Edward Medical University, Lahore
Lahore, Punjab Province, Pakistan
Related Publications (3)
Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005 Nov;34(6):614-9. doi: 10.1093/ageing/afi196.
PMID: 16267188BACKGROUNDStaff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5.
PMID: 28486769BACKGROUNDBerg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health. 1992 Jul-Aug;83 Suppl 2:S7-11.
PMID: 1468055BACKGROUND
Study Officials
- PRINCIPAL INVESTIGATOR
Amna Zia, PhD. Scholar
King Edward Medical University, Lahore
- PRINCIPAL INVESTIGATOR
Muhammad Saad Khalid
King Edward Medical University, Lahore
- STUDY DIRECTOR
Rizwan Haider, PhD. Scholar
King Edward Medical University, Lahore
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Masking Details
- Participants will be blinded to group allocation by providing both groups with supervised physiotherapy sessions of similar duration and structure, without disclosure of group-specific intervention details. Outcome assessors will be blinded to treatment allocation. Due to the nature of the intervention, care providers delivering the physiotherapy cannot be blinded.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Physiotherapist/ Lecturer
Study Record Dates
First Submitted
January 18, 2026
First Posted
January 26, 2026
Study Start
December 29, 2025
Primary Completion
March 29, 2026
Study Completion
April 29, 2026
Last Updated
January 26, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared publicly due to the single-center nature of the study, institutional data protection policies, and the absence of participant consent for public data sharing. De-identified, aggregated results will be reported in publications and presentations.